4 registrations that name chia Seed as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 4 registrations
Status
5US sites across 4 states
1
2 to 4
5 to 19
20 or more
All 4 registrations
RecruitingNCT07218640
Aimmune Longitudinal Collaboration Study
No phase
Aimmune Therapeutics, Inc.
About 60 people
Starts Oct 2025 (estimated)
In plain words A study of chia Seed in people 18 to 50, run by Aimmune Therapeutics, Inc.. It plans to enroll about 60 people at 2 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 50; healthy volunteers accepted. Conditions: Stool Spore Colony Forming Units; Microbiome Composition; Dietary Fiber; Stress.
18 years of age or greater
Able to sign informed consent in English
Households (2 or more adults) or individuals who are willing to provide a minimum of 3 separate stool samples per week and utilize a manual stool sampling tool.
Are generally healthy
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Chia seeds
Registered summary
This study will include healthy households around the Irvine, CA area (based local to employees) and Tempe, AZ and Philadelphia, PA sites that will be instructed to take a daily fiber supplement (2.5 tablespoons of chia seeds \[\~10.3g of fiber\] which is one serving) for two months. Participants will use a stool sampling tool to facilitate ease of stool collection, or they may donate at a study site. The full summary is on the listing.
Where, as registered
2 US sites in 1 state.
RecruitingNCT07553234
Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer Treatment
No phase
University of Chicago
About 20 people
Started Sep 21, 2026
In plain words A study of chia Seed in people 18 and older, run by University of Chicago. It plans to enroll about 20 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Breast Cancer.
Be willing and able to provide written informed consent for the trial
Be a male or female subject 18 years of age on day of signing informed consent.
Histologically proven infiltrating carcinoma of the breast on core needle biopsy that is:
Estrogen receptor (ER) and progesterone receptors (PR) positive in primary tumour pre-treatment defined as >1% of cells expressing hormonal receptors via IHC analysis by local laboratory assessment.
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Stool Sampling; Chia Seeds
Registered summary
This study will be conducted in 2 sequential parts. The first part will be a prospective, observational study. This will be followed by a small interventional, pilot study involving use of fiber supplement (chia seeds). The study aims to evaluate the relationship between the gut microbiome (a diverse ecosystem of microorganisms that affects your health and well-being) and treatment-related gastrointestinal toxicities in patients with HR+/HER2- breast cancer receiving abemaciclib plus endocrine therapy.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07343908
Impact of Chia Seeds on Human Breast Milk Composition
No phase
University of Oklahoma
About 80 people
Starts Aug 2026 (estimated)
In plain words A study of chia Seed in people 18 to 45, run by University of Oklahoma. It plans to enroll about 80 people at 2 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 45. Conditions: Obesity and Overweight; Breastfeeding, Exclusive.
pre-pregnancy BMI >25 kg/m²
Maternal age 18 - 45 years at time of delivery
Singleton pregnancy
Vaginal delivery
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Chia seeds
Registered summary
The investigators' over-arching hypothesis is that mechanical and compositional properties of chia seeds supplemented during lactation diminish obesity-induced intestinal inflammation and barrier dysfunction. The investigators hypothesize these changes will result in: 1) reduced maternal systemic inflammation (serum CRP and IL-6) and increased gut microbial diversity and richness, 2) reduced HM fat and inflammatory markers, metrics the research team have demonstrated differ in tandem with maternal metabolic health and 3) improved infant growth/body composition. The full summary is on the listing.
Where, as registered
2 US sites in 2 states.
Not yet recruitingNCT07797049
Chia Seed Impact on Postprandial Glycemia and Appetite in Overweight Adults
No phase
University of Veterinary and Animal Sciences, Lahore - Pakistan
About 30 people
Starts Aug 28, 2026 (estimated)
In plain words A study of chia Seed in people 18 to 40, run by University of Veterinary and Animal Sciences, Lahore - Pakistan. It plans to enroll about 30 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 40; healthy volunteers accepted. Conditions: Overweight Adults; Postprandial Glycemia; Appetite Response.
Age: 18-40 years
BMI: 25-29.9 kg/m²
Male and female participants
Normoglycemic participants
The exclusion criteria are on the listing.
What it tests, as registered
Chia Seed (Salvia hispanica L.) Beverage
Registered summary
Overweight and obesity affect nearly 2.5 billion adults worldwide and increase cardiometabolic risk. Postprandial glucose excursions are influenced by diet and inactivity and predict metabolic disorders, while South Asians, particularly Pakistanis, are more vulnerable due to genetic and lifestyle factors and processed diets. This study evaluates the impact of chia seed (Salvia hispanica L.) ingestion on postprandial glycemia and appetite in overweight adults, supporting UN Sustainable Development Goal 3 (Good Health and Well-being). The full summary is on the listing.